| Designations: | SH-SY5Y |
| Depositors: | JL Biedler |
| Biosafety Level: | 1 |
| Shipped: | frozen |
| Medium & Serum: | See Propagation |
| Growth Properties: | mixed, adherent and suspension |
| Organism: | Homo sapiens （human） |
| Morphology: | epithelial
 |
| Source: | Organ: brain
Disease: neuroblastoma
Derived from metastatic site: bone marrow |
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| CRL-2266 |
| Restrictions: | NOTE: SH-SY5Y was deposited at the ATCC by June L. Biedler, Memorial Sloan-Kettering Cancer Center. SH-SY5Y is distributed for academic research purposes only. Memorial Sloan-Kettering releases the line subject to the following: 1.） SH-SY5Y or its products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.） Any proposed commercial use of SH-SY5Y including any use by a for-profit entity must first be negotiated with Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone （212） 639-6181; （212） 717-3439. |
| Isolation: | Isolation date: 1970 |
| Applications: | transfection host （Roche FuGENE® Transfection Reagents
technology from amaxa） |
| Antigen Expression: | Blood Type A; Rh+ |
| DNA Profile （STR）: | Amelogenin: X
CSF1PO: 11
D13S317: 11
D16S539: 8,13
D5S818: 12
D7S820: 7,10
THO1: 7,10
TPOX: 8,11
vWA: 14,18 |
| Cytogenetic Analysis: | modal number = 47; the cells possess a unique marker comprised of a chromosome 1 with a complex insertion of an additional copy of a 1q segment into the long arm, resulting in trisomy of 1q [22554] |
| Age: | 4 years |
| Gender: | female |
| Comments: | SH-SY5Y cells have a reported saturation density greater than 1 X 10（6） cells/sq cm. They are reported to exhibit moderate levels of dopamine beta hydroxylase activity [PubMed ID: 29704]. |
| Propagation: | ATCC complete growth medium: The base medium for this cell line is a 1:1 mixture of ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003, and F12 Medium. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide （CO2）, 5%
Temperature: 37.0°C |
| Subculturing: | Protocol: These cells grow as a mixture of floating and adherent cells. The cells grow as clusters of neuroblastic cells with multiple, short, fine cell processes （neurites）. Cells will aggregate, form clumps and float.
Remove the medium with the floating cells, and recover the cells by centrifugation. Rinse the adherent cells with fresh 0.25% trypsin, 0.53 mM EDTA solution, add an additional 1 to 2 ml of trypsin solution, and let the culture sit at room temperature （or at 37C） until the cells detach. Add fresh medium, aspirate, combine with the floating cells recovered above and dispense into new flasks.
Subcultivation Ratio: A subcultivation ratio of 1:20 to 1:50 is recommended
Medium Renewal: Every 4 to 7 days |
| Preservation: | Freeze medium: Complete growth medium supplemented with 5% （v/v） DMSO
Storage temperature: liquid nitrogen vapor phase |
| Doubling Time: | 48 hrs |
| Related Products: | recommended serum:ATCC 30-2020
parental cell line:ATCC HTB-11 |
| References: | 22554: Ross RA, et al. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J. Natl. Cancer Inst. 71: 741-749, 1983. PubMed: 6137586
23032: Biedler JL, et al. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 38: 3751-3757, 1978. PubMed: 29704 |
